APOA1 (Apolipoprotein A-I) variants and mutations
APOA1 (also known as Apolipoprotein A-I) is a human protein-coding gene encoding an apolipoprotein A-I protein. It is the principal protein scaffold of HDL and activates LCAT, supporting cholesterol efflux from peripheral tissues and reverse cholesterol transport. Pathogenic variants can cause very low HDL cholesterol, familial amyloidosis in some alleles, or altered cardiovascular risk. This analysis covers 729 APOA1 variants and mutations. Of these, 88% have computational variant effect predictions. Disease context includes hypoalphalipoproteinemia, primary, 2, familial visceral amyloidosis, and Familial renal amyloidosis. Example APOA1 variants include K2N, K2Q, and A4E.
Variant analysis overview
- Gene: APOA1
- Protein: Apolipoprotein A-I
- UniProt accession: P02647
- Organism: Homo sapiens
- Variants analyzed: 729
- Variant scope: all variants
- Completed: 2026-08-19
Variant and mutation evidence
- Variant composition: 427 unspecified-consequence records; 126 missense variants; 2 in-frame insertions; 136 synonymous variants; 9 in-frame deletions; 17 frameshift variants; 8 stop-gained variants; 3 splice-region variants; 1 substitution
- Prediction scores: 640 variants have prediction scores (88% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: hypoalphalipoproteinemia, primary, 2, familial visceral amyloidosis, Familial renal amyloidosis, hypoalphalipoproteinemia, primary, 2, intermediate, apolipoprotein A-I deficiency, dengue disease, AL amyloidosis, Abnormality of the cardiovascular system, amyloidosis, Tangier disease, AApoAI amyloidosis, Familial renal amyloidosis due to Apolipoprotein AI variant.
Protein structure and variant hotspots
- Protein features: 11 post-translational modification sites.
- PTM context: 22 variants overlap post-translational modification sites.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, 3D Hotspot Analysis, Interaction Network Analysis, Protein Data Bank, AlphaFold DB, gnomAD constraint, Open Targets, MaveDB, LitVar.
Notable APOA1 variants
Examples include K2N, K2Q, A4E, A4V, V5E, T7I, A9T, V10M. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- K2N (p.Lys2Asn), Ensembl rs1941582579, REVEL 0.41, CADD 23.50
- K2Q (p.Lys2Gln), TOPMed rs1941582649, REVEL 0.45, CADD 23.90
- A4E (p.Ala4Glu), rs1265273561, ClinGen CA382722492, ClinVar RCV003865770, AlphaMissense 0.06, MetaLR 0.05, Uncertain significance, not provided
- A4V (p.Ala4Val), rs1265273561, ClinGen CA382722494, cosmic curated COSV52635, ClinVar RCV001896030, REVEL 0.08, AlphaMissense 0.06, Uncertain significance, not provided; not specified
- V5E (p.Val5Glu), cosmic curated COSV10456
- T7I (p.Thr7Ile), NCI-TCGA TCGA novel, REVEL 0.12, CADD 17.50, Variant assessed as somatic; moderate impact.
- A9T (p.Ala9Thr), TOPMed rs1303994071
- V10M (p.Val10Met), rs750125257, ClinGen CA6289929, NCI-TCGA Cosmic COSV5263, cosmic curated COSV52635, REVEL 0.13, CADD 20.20, Conflicting interpretations, Cardiovascular phenotype; Familial visceral amyloidosis, Ostertag type; not prov
- F12L (p.Phe12Leu), Ensembl rs1318581391, REVEL 0.18, CADD 23.80, Uncertain significance, not provided
- L13R (p.Leu13Arg), Ensembl rs1941581716, REVEL 0.69, CADD 27.00
- T14M (p.Thr14Met), rs778560581, ClinGen CA6289928, cosmic curated COSV52635, ClinVar RCV000779743, REVEL 0.45, CADD 32.00, Uncertain significance, Cardiovascular phenotype; not provided; Familial visceral amyloidosis, Ostertag
- G15A (p.Gly15Ala), Ensembl rs2134233729, Pathogenic
- G15C (p.Gly15Cys), cosmic curated COSV52635, Ensembl rs866736886
- G15E (p.Gly15Glu), cosmic curated COSV52635
- G15V (p.Gly15Val), Ensembl rs2134233729, cosmic curated COSV52636, Pathogenic
- G15G (p.Gly15Gly), rs1941573861, gnomAD 11-116837156-C-T, CADD 17.30
- S16N (p.Ser16Asn), Ensembl rs2134233719, Uncertain significance
- S16S (p.Ser16Ser), rs1941573782, gnomAD 11-116837153-G-A, CADD 13.80
- Q17H (p.Gln17His), rs2540295476, ClinGen CA382721485, ClinVar RCV003151585, Uncertain significance, not specified
- Q17K (p.Gln17Lys), rs2540295489, ClinGen CA382721524, ClinVar RCV003723992, Uncertain significance, not provided
- Q17L (p.Gln17Leu), NCI-TCGA Cosmic COSV9936, cosmic curated COSV99369, Variant assessed as somatic; moderate impact.
- Q17Q (p.Gln17Gln), gnomAD 11-116837150-C-T, CADD 11.60
- Q17P (p.Gln17Pro), rs1941573709, gnomAD 11-116837151-T-TG, CADD 32.00
- Q17R (p.Gln17Arg), gnomAD 11-116837151-TG-T, CADD 32.00
- A18V (p.Ala18Val), NCI-TCGA Cosmic COSV5263, cosmic curated COSV52635, Variant assessed as somatic; moderate impact.
- A18D (p.Ala18Asp), gnomAD 11-116837148-G-T, REVEL 0.91, CADD 29.30
- R19P (p.Arg19Pro), ExAC rs777407596, gnomAD rs777407596, Uncertain significance
- R19Q (p.Arg19Gln), rs777407596, ClinGen CA382721459, ClinVar RCV003665596, ExAC rs777407596, REVEL 0.32, CADD 23.20, Uncertain significance, not provided
- R19W (p.Arg19Trp), rs371084971, ClinGen CA6289907, cosmic curated COSV52635, ClinVar RCV001940062, REVEL 0.18, CADD 24.90, Uncertain significance, not provided
- R19R (p.Arg19Arg), rs571564084, gnomAD 11-116837144-C-T, CADD 12.60
- R19G (p.Arg19Gly), gnomAD 11-116837146-G-C, REVEL 0.43, CADD 26.60
- H20Y (p.His20Tyr), gnomAD 11-116837143-G-A, REVEL 0.09, CADD 18.40
- F21L (p.Phe21Leu), TOPMed rs1285743895, gnomAD rs1285743895, CADD 17.90, Likely benign
- F21V (p.Phe21Val), Ensembl rs1591331428
- F21F (p.Phe21Phe), rs1285743895, gnomAD 11-116837138-G-A, CADD 12.50
- W22C (p.Trp22Cys), gnomAD 11-116837135-C-G, REVEL 0.63, CADD 27.40
- W22R (p.Trp22Arg), gnomAD 11-116837137-A-G, REVEL 0.61, CADD 26.30
- Q23* (p.Gln23Ter), rs387906570, ClinGen CA127571, ClinVar RCV002514117, ClinVar RCV004555839, CADD 40.00, Pathogenic
- Q23K (p.Gln23Lys), TOPMed rs387906570, gnomAD rs387906570, REVEL 0.55, CADD 26.50, Pathogenic
- Q23R (p.Gln23Arg), gnomAD rs1941572793, REVEL 0.62, CADD 26.80
- Q23Q (p.Gln23Gln), gnomAD 11-116837132-C-T, CADD 11.20
- Q23L (p.Gln23Leu), gnomAD 11-116837133-T-A, REVEL 0.62, CADD 27.70
- Q24H (p.Gln24His), gnomAD rs1941572699
- D25E (p.Asp25Glu), rs2540295354, ClinGen CA382721229, ClinVar RCV003721074, Uncertain significance, not provided
- D25G (p.Asp25Gly), rs1223595170, ClinGen CA382721235, ClinVar RCV002298052, gnomAD rs1223595170, REVEL 0.45, CADD 29.20, Uncertain significance, not provided
- E26K (p.Glu26Lys), NCI-TCGA Cosmic COSV5263, cosmic curated COSV52636, Variant assessed as somatic; moderate impact.
- E26Q (p.Glu26Gln), rs1197166743, ClinGen CA382721223, ClinVar RCV002815764, gnomAD rs1197166743, REVEL 0.21, CADD 25.50, Uncertain significance, not provided; Cardiovascular phenotype
- E26D (p.Glu26Asp), gnomAD 11-116837123-T-G, REVEL 0.06, CADD 0.00
- P27H (p.Pro27His), rs121912720, ClinGen CA6289902, ClinVar RCV001822795, ClinVar RCV001869774, REVEL 0.37, CADD 25.00, Uncertain significance, not specified; not provided; Cardiovascular phenotype
- P27L (p.Pro27Leu), 1000Genomes rs121912720, ESP rs121912720, ExAC rs121912720, TOPMed rs121912720, REVEL 0.36, CADD 25.40, Pathogenic
- P27R (p.Pro27Arg), rs121912720, ClinGen CA127552, ClinVar RCV000019503, UniProt VAR 000606, REVEL 0.34, CADD 25.00, Pathogenic, APOLIPOPROTEIN A-I (MUNSTER3C)
- P27S (p.Pro27Ser), rs200213347, ClinGen CA6289903, ClinVar RCV004417720, ClinVar RCV005104554, REVEL 0.28, CADD 23.30, Uncertain significance, Cardiovascular phenotype; not provided
- P27T (p.Pro27Thr), 1000Genomes rs200213347, ExAC rs200213347, TOPMed rs200213347, gnomAD rs200213347, REVEL 0.26, CADD 23.20, Uncertain significance
- P27P (p.Pro27Pro), rs1242024145, gnomAD 11-116837120-G-A, CADD 6.73
- P28L (p.Pro28Leu), ESP rs121912721, ExAC rs121912721, TOPMed rs121912721, gnomAD rs121912721, REVEL 0.36, CADD 22.30, Pathogenic, in Munster-3B
- P28R (p.Pro28Arg), rs121912721, ClinGen CA127555, ClinVar RCV000019504, ClinVar RCV001851952, REVEL 0.32, CADD 18.30, Uncertain significance, Hypoalphalipoproteinemia, primary, 2; Hypoalphalipoproteinemia, primary, 2, inte
- P28S (p.Pro28Ser), rs751415951, ClinGen CA6289901, ClinVar RCV003293729, ExAC rs751415951, REVEL 0.42, CADD 22.60, Uncertain significance, Cardiovascular phenotype
- P28P (p.Pro28Pro), rs369066087, gnomAD 11-116837117-G-C, CADD 3.69
- Q29H (p.Gln29His), TOPMed rs751028421, REVEL 0.12, CADD 16.90, Uncertain significance, Familial amyloid polyneuropathy, Iowa type; Hypoalphalipoproteinemia, primary, 2
- Q29K (p.Gln29Lys), TOPMed rs1254205437, gnomAD rs1254205437, REVEL 0.04, CADD 10.30
- Q29R (p.Gln29Arg), rs753348565, gnomAD 11-116837115-TG-T, CADD 20.20
- Q29P (p.Gln29Pro), rs753348565, gnomAD 11-116837115-T-TG, CADD 23.50
- S30G (p.Ser30Gly), rs147246779, ClinGen CA229325329, cosmic curated COSV99369, ClinVar RCV004322730, REVEL 0.19, CADD 5.78, Uncertain significance, Cardiovascular phenotype; Hypoalphalipoproteinemia, primary, 2, intermediate; Hy
- S30N (p.Ser30Asn), gnomAD rs1425007091, REVEL 0.18, CADD 5.56
- S30R (p.Ser30Arg), 1000Genomes rs563067047, ExAC rs563067047, TOPMed rs563067047, gnomAD rs563067047, REVEL 0.09, CADD 11.30, Uncertain significance
- S30S (p.Ser30Ser), rs563067047, gnomAD 11-116837111-G-A, CADD 3.70
- S30E (p.Ser30Glu), gnomAD 11-116837114-C-CT, CADD 23.70
- P31A (p.Pro31Ala), rs764283540, ClinGen CA6289897, ClinVar RCV003841605, ExAC rs764283540, REVEL 0.06, CADD 0.95, Uncertain significance, not provided
- P31L (p.Pro31Leu), cosmic curated COSV52636, TOPMed rs1457511298, gnomAD rs1457511298, REVEL 0.17, CADD 19.20
- P31S (p.Pro31Ser), rs764283540, ClinGen CA382721059, ClinVar RCV003849684, ExAC rs764283540, REVEL 0.03, CADD 0.59, Uncertain significance, not provided
- P31P (p.Pro31Pro), gnomAD 11-116837108-G-A, CADD 3.06
- W32C (p.Trp32Cys), NCI-TCGA TCGA novel, Uncertain significance, Cardiovascular phenotype
- W32* (p.Trp32Ter), gnomAD 11-116837106-C-T, CADD 37.00
- R34* (p.Arg34Ter), rs1373700967, ClinGen CA382720980, NCI-TCGA Cosmic COSV5263, cosmic curated COSV52635, CADD 35.00, Pathogenic, in Baltimore
- R34G (p.Arg34Gly), rs1373700967, ClinGen CA382720987, ClinVar RCV003325740, ClinVar RCV006342937, REVEL 0.26, CADD 23.10, Uncertain significance, not provided; Cardiovascular phenotype
- R34L (p.Arg34Leu), rs28929476, ClinGen CA127563, ClinVar RCV000019513, ClinVar RCV001508677, REVEL 0.37, CADD 18.10, Uncertain significance, Hypoalphalipoproteinemia, primary, 2, intermediate; Hypoalphalipoproteinemia, pr
- R34Q (p.Arg34Gln), cosmic curated COSV52636, ESP rs28929476, ExAC rs28929476, TOPMed rs28929476, REVEL 0.02, CADD 11.40, Uncertain significance, not provided
- R34R (p.Arg34Arg), rs1448433450, gnomAD 11-116837099-T-C, CADD 9.01
- V35L (p.Val35Leu), rs1476964300, NCI-TCGA Cosmic COSV5263, cosmic curated COSV52635, TOPMed rs1476964300, AlphaMissense 0.29, MetaLR 0.18, Uncertain significance
- V35M (p.Val35Met), rs1476964300, ClinGen CA382720971, ClinVar RCV001996517, ClinVar RCV002389011, REVEL 0.05, AlphaMissense 0.29, Uncertain significance, Cardiovascular phenotype; not provided
- K36K (p.Lys36Lys), rs775510323, gnomAD 11-116837093-C-T, CADD 11.90
- K36T (p.Lys36Thr), gnomAD 11-116837094-T-G, REVEL 0.42, CADD 24.50
- D37A (p.Asp37Ala), Ensembl rs1591331308
- D37N (p.Asp37Asn), TOPMed rs1941570680, gnomAD rs1941570680, REVEL 0.49, CADD 26.90
- D37G (p.Asp37Gly), gnomAD 11-116837091-T-C, REVEL 0.66, CADD 26.60
- D37Y (p.Asp37Tyr), gnomAD 11-116837092-C-A, REVEL 0.72, CADD 27.10
- L38V (p.Leu38Val), rs745889664, ClinGen CA382719410, ClinVar RCV002695240, ClinVar RCV005465787, REVEL 0.02, CADD 7.41, Uncertain significance, Cardiovascular phenotype; not provided
- L38L (p.Leu38Leu), rs772574430, gnomAD 11-116837087-C-G, CADD 0.93
- L38W (p.Leu38Trp), rs768017979, gnomAD 11-116837088-AG-A, CADD 20.70
- L38M (p.Leu38Met), gnomAD 11-116837089-G-T, REVEL 0.02, CADD 7.88
- A39T (p.Ala39Thr), cosmic curated COSV52635, Uncertain significance, Cardiovascular phenotype
- A39V (p.Ala39Val), rs746314593, ClinGen CA6289893, ClinVar RCV000308803, ClinVar RCV000398922, REVEL 0.07, CADD 3.80, Conflicting interpretations, Cardiovascular phenotype; Familial visceral amyloidosis, Ostertag type; Hypoalph
- A39A (p.Ala39Ala), rs1941570232, gnomAD 11-116837084-G-A, CADD 5.81
- T40A (p.Thr40Ala), cosmic curated COSV99369, ExAC rs774753857, gnomAD rs774753857, REVEL 0.18, CADD 8.79
- T40N (p.Thr40Asn), TOPMed rs1591331280, gnomAD rs1591331280, REVEL 0.17, CADD 5.42
- T40T (p.Thr40Thr), gnomAD 11-116837081-A-G, CADD 5.08
- V41L (p.Val41Leu), 1000Genomes rs201148448, ExAC rs201148448, TOPMed rs201148448, gnomAD rs201148448, REVEL 0.06, CADD 10.00
- V41V (p.Val41Val), gnomAD 11-116837078-C-T, CADD 8.62
- V41A (p.Val41Ala), gnomAD 11-116837079-A-G, REVEL 0.20, CADD 22.60
- Y42* (p.Tyr42Ter), rs1591331259, gnomAD rs1591331259, ClinGen CA382719292, ClinVar RCV003314532, Likely pathogenic
- Y42Y (p.Tyr42Tyr), rs1591331259, gnomAD 11-116837075-G-A, CADD 2.47
- V43L (p.Val43Leu), rs373545875, ClinGen CA229325261, ClinVar RCV001108697, ClinVar RCV001108698, REVEL 0.09, CADD 6.99, Likely benign, Familial visceral amyloidosis, Ostertag type; Hypoalphalipoproteinemia, primary
- V43M (p.Val43Met), rs373545875, ClinGen CA6289889, ClinVar RCV002017428, ClinVar RCV002386878, REVEL 0.24, CADD 13.70, Uncertain significance, Familial visceral amyloidosis, Ostertag type; Hypoalphalipoproteinemia, primary
- V43V (p.Val43Val), rs1206004844, gnomAD 11-116837072-C-T, CADD 11.10
- D44E (p.Asp44Glu), ExAC rs755740688, TOPMed rs755740688, gnomAD rs755740688, REVEL 0.07, CADD 0.02, Uncertain significance, Familial amyloid polyneuropathy, Iowa type; Hypoalphalipoproteinemia, primary, 2
- D44N (p.Asp44Asn), rs1315705365, ClinGen CA382719254, ClinVar RCV002006484, gnomAD rs1315705365, REVEL 0.15, CADD 20.20, Uncertain significance, not provided
- V45A (p.Val45Ala), Ensembl rs1591331231
- V45M (p.Val45Met), rs2134232994, ClinGen CA382719189, ClinVar RCV001898097, Ensembl rs2134232994, AlphaMissense 0.17, MetaLR 0.08, Uncertain significance, not provided
- L46P (p.Leu46Pro), gnomAD rs1941569410, REVEL 0.47, CADD 21.80
- L46V (p.Leu46Val), Ensembl rs1591331223
- L46L (p.Leu46Leu), rs747688781, gnomAD 11-116837063-G-A, CADD 4.24
- D48A (p.Asp48Ala), Ensembl rs1941569247, REVEL 0.13, CADD 21.30
- D48G (p.Asp48Gly), rs1941569247, ClinGen CA382719011, ClinVar RCV003695744, REVEL 0.31, CADD 23.60, Uncertain significance, not provided
- S49I (p.Ser49Ile), ExAC rs755026583, TOPMed rs755026583, gnomAD rs755026583, REVEL 0.27, CADD 22.60
- S49N (p.Ser49Asn), rs755026583, NCI-TCGA Cosmic COSV5263, cosmic curated COSV52636, ExAC rs755026583, REVEL 0.15, CADD 14.30, Uncertain significance, not provided
- S49R (p.Ser49Arg), ExAC rs780794079, gnomAD rs780794079, cosmic curated COSV10957, REVEL 0.21, CADD 22.50
- S49S (p.Ser49Ser), rs757974682, gnomAD 11-116837054-G-A, CADD 4.15
- G50C (p.Gly50Cys), cosmic curated COSV10632
- G50R (p.Gly50Arg), rs28931574, ClinGen CA127561, ClinVar RCV000019506, ClinVar RCV003556050, AlphaMissense 0.12, MetaLR 0.48, Pathogenic, Hypoalphalipoproteinemia, primary, 2; Hypoalphalipoproteinemia, primary, 2, inte
- G50S (p.Gly50Ser), rs28931574, ClinGen CA6289883, ClinVar RCV002389666, ClinVar RCV005097548, REVEL 0.52, AlphaMissense 0.12, Uncertain significance, not provided; Cardiovascular phenotype
- G50V (p.Gly50Val), gnomAD rs1333457474, Uncertain significance, Familial amyloid polyneuropathy, Iowa type; Hypoalphalipoproteinemia, primary, 2
- R51T (p.Arg51Thr), TOPMed rs1233547311, gnomAD rs1233547311, REVEL 0.27, CADD 17.00
- R51R (p.Arg51Arg), rs758106382, gnomAD 11-116837048-T-C, CADD 12.60
- R51K (p.Arg51Lys), gnomAD 11-116837049-C-T, REVEL 0.07, CADD 7.56
- D52D (p.Asp52Asp), gnomAD 11-116837045-G-A, CADD 2.67
- D52N (p.Asp52Asn), gnomAD 11-116837047-C-T, REVEL 0.40, CADD 25.50
- Y53* (p.Tyr53Ter), gnomAD rs1177384340, CADD 34.00
- Y53C (p.Tyr53Cys), rs750185173, ClinGen CA6289881, ClinVar RCV001193576, ClinVar RCV001876253, REVEL 0.29, CADD 19.40, Uncertain significance, APOA1-related disorder; Hypoalphalipoproteinemia, primary, 2, intermediate; Fami
- Y53Y (p.Tyr53Tyr), rs1177384340, gnomAD 11-116837042-A-G, CADD 5.93
- V54V (p.Val54Val), rs193922099, gnomAD 11-116837039-C-G, CADD 7.71
- V54M (p.Val54Met), gnomAD 11-116837041-C-T, REVEL 0.20, CADD 14.50
- S55A (p.Ser55Ala), TOPMed rs1269670005
- S55P (p.Ser55Pro), TOPMed rs1269670005
- Q56* (p.Gln56Ter), rs121912725, ClinGen CA127574, ClinVar RCV004555840, Ensembl rs121912725, Pathogenic
- Q56H (p.Gln56His), ExAC rs760886281, TOPMed rs760886281, gnomAD rs760886281, Likely benign
- Q56R (p.Gln56Arg), TOPMed rs1480675909, REVEL 0.58, CADD 24.50
- Q56Q (p.Gln56Gln), rs760886281, gnomAD 11-116837033-C-T, CADD 7.98
- F57L (p.Phe57Leu), gnomAD 11-116837030-A-C, REVEL 0.12, CADD 7.30
- E58Q (p.Glu58Gln), gnomAD 11-116837029-C-G, REVEL 0.31, CADD 23.50
- G59A (p.Gly59Ala), ExAC rs775559386, TOPMed rs775559386, gnomAD rs775559386, REVEL 0.06, CADD 0.21, Conflicting interpretations, not provided; Cardiovascular phenotype
- G59D (p.Gly59Asp), rs775559386, ClinGen CA382718470, ClinVar RCV004518622, ExAC rs775559386, REVEL 0.05, CADD 9.61, Uncertain significance, Cardiovascular phenotype
- G59V (p.Gly59Val), rs775559386, ClinGen CA6289879, ClinVar RCV002625975, ExAC rs775559386, REVEL 0.05, CADD 9.40, Uncertain significance, not provided
- G59G (p.Gly59Gly), rs1941567923, gnomAD 11-116837024-G-C, CADD 3.87
- S60A (p.Ser60Ala), rs199759119, ClinGen CA6289877, ClinVar RCV001873509, ClinVar RCV002411631, REVEL 0.64, CADD 22.80, Conflicting interpretations, not specified; Cardiovascular phenotype; not provided
- S60F (p.Ser60Phe), cosmic curated COSV52636, REVEL 0.71, CADD 23.30
- S60P (p.Ser60Pro), ESP rs199759119, ExAC rs199759119, TOPMed rs199759119, gnomAD rs199759119, REVEL 0.75, CADD 23.40, Benign
- S60S (p.Ser60Ser), rs774804784, gnomAD 11-116837021-G-A, CADD 3.82
- A61T (p.Ala61Thr), rs12718465, ClinGen CA6289875, cosmic curated COSV10584, ClinVar RCV000335636, REVEL 0.04, CADD 7.11, Benign, Hypoalphalipoproteinemia, primary, 2, intermediate; Cardiovascular phenotype; no
- A61A (p.Ala61Ala), rs5071, gnomAD 11-116837018-G-A, CADD 5.49
- L62F (p.Leu62Phe), ExAC rs763248522, TOPMed rs763248522, gnomAD rs763248522, REVEL 0.06, CADD 22.40, Likely benign
- L62W (p.Leu62Trp), Ensembl rs17407917
- L62L (p.Leu62Leu), rs763248522, gnomAD 11-116837015-C-T, CADD 10.20
- G63E (p.Gly63Glu), NCI-TCGA Cosmic COSV9936, cosmic curated COSV99369, Variant assessed as somatic; moderate impact.
- G63G (p.Gly63Gly), gnomAD 11-116837012-T-C, CADD 7.84
- K64E (p.Lys64Glu), NCI-TCGA Cosmic COSV5263, cosmic curated COSV52635, Variant assessed as somatic; moderate impact.
- K64Q (p.Lys64Gln), cosmic curated COSV10803
- K64R (p.Lys64Arg), rs2540294515, ClinGen CA382718286, ClinVar RCV002410663, Uncertain significance, Cardiovascular phenotype
- Q65Q (p.Gln65Gln), rs773584936, gnomAD 11-116837006-C-T, CADD 9.71
- L66=, rs540974091, NCI-TCGA Cosmic COSV9936, Variant assessed as somatic; low impact.
- L66L (p.Leu66Leu), rs540974091, gnomAD 11-116837003-T-C, CADD 9.53
- N67K (p.Asn67Lys), ExAC rs746552681, TOPMed rs746552681, gnomAD rs746552681, REVEL 0.49, CADD 25.60
- L68Q (p.Leu68Gln), gnomAD 11-116836409-A-T, REVEL 0.76, CADD 28.90
- L68L (p.Leu68Leu), gnomAD 11-116836410-G-A, CADD 16.40
- L68* (p.Leu68Ter), gnomAD 11-116836410-G-GG, CADD 33.00
- L70F (p.Leu70Phe), gnomAD 11-116836404-G-A, REVEL 0.63, CADD 24.90
- L71I (p.Leu71Ile), cosmic curated COSV52635
- L71V (p.Leu71Val), ExAC rs779553097, gnomAD rs779553097, REVEL 0.06, CADD 13.70
- L71L (p.Leu71Leu), rs565203809, gnomAD 11-116836399-A-C, CADD 10.60
- L71del (p.Leu71del), rs770007065, gnomAD 11-116836399-AAGG, CADD 17.00
- L71P (p.Leu71Pro), gnomAD 11-116836400-A-G, REVEL 0.44, CADD 23.40
- D72E (p.Asp72Glu), TOPMed rs1941550540
- D72N (p.Asp72Asn), rs2540291863, ClinGen CA382717670, ClinVar RCV003318987, Uncertain significance, not provided
- D72D (p.Asp72Asp), gnomAD 11-116836396-G-A, CADD 9.10
- D72V (p.Asp72Val), gnomAD 11-116836397-T-A, REVEL 0.56, CADD 26.90
- D72G (p.Asp72Gly), gnomAD 11-116836397-T-C, REVEL 0.47, CADD 27.30
- N73S (p.Asn73Ser), TOPMed rs1030881446, Uncertain significance, Cardiovascular phenotype
- W74R (p.Trp74Arg), rs121912726, ClinGen CA127577, ClinVar RCV003556051, ClinVar RCV004555842, AlphaMissense 0.84, MetaLR 0.48, Pathogenic, not provided
- D75N (p.Asp75Asn), gnomAD 11-116836389-C-T, REVEL 0.40, CADD 24.00
- D75E (p.Asp75Glu), rs772355721, []
- S76N (p.Ser76Asn), rs1226109269, ClinGen CA382717440, ClinVar RCV002585026, ClinVar RCV004073385, REVEL 0.30, CADD 14.90, Uncertain significance, Cardiovascular phenotype; not provided
Public APOA1 analysis runs
- APOA1 analysis run — APOA1 (729 variants) — completed 2026-08-19